RxDoctor Payments Data

Jerry Obritsch, MD

Obstetrics & Gynecology · Bismarck, NDNPI 1093769291

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $17,531 of the $22,529 with a category attached, or 77.8%. AbbVie accounts for 84.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $12,079 and has fallen 98.7% since, to $162 in 2023. Among obstetrics & gynecology clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,529in general payments, 2019–2025

Across 102 payments — averaging $220.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$19K
  • Axonics, Inc.$2K
  • Medtronic$648
  • Astellas Pharma US Inc$298
  • Coloplast$155
  • Davol Inc.$102
  • plus $282 from 9 others

What the payments were for

  • Speaking & faculty fees$17,53178%
  • Travel & lodging$2,52911%
  • Food & beverage$2,37911%
  • Education$900%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,529 in reported general payments places this provider in the 95th percentile of 86 obstetrics & gynecology providers in North Dakota.

See all obstetrics & gynecology providers in North Dakota

Medicare billing

Part B allowed, 2024
$108,201
Medicare patients
467
Services billed
2,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron35$19,259
Estradiol67$6,983
Oxybutynin Chloride ErOxybutynin Chloride17$143
Ciprofloxacin Hcl26$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$298$19,25935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 86 obstetrics & gynecology providers in North Dakota.

Other obstetrics & gynecology in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →